SAGE Therapeutics ( (SAGE) ) has shared an announcement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Biogen has informed Sage Therapeutics of its decision to terminate their collaboration on the SAGE-324 molecule, effective February 17, 2025, following negative results from a recent clinical study. Despite this, the partnership between the two companies persists for the development and commercialization of ZURZUVAE®, an FDA-approved treatment for postpartum depression. As a consequence of the termination, Biogen’s licenses related to the SAGE-324 molecule will expire, with Sage receiving perpetual rights to certain Biogen technologies for the molecule.
Find detailed analytics on SAGE stock on TipRanks’ Stock Analysis page.
